Show simple item record

dc.contributor.authorNøst, Therese Haugdahl
dc.contributor.authorAlcala, Karine
dc.contributor.authorUrbarova, Ilona
dc.contributor.authorByrne, Karl Smith
dc.contributor.authorGuida, Florence
dc.contributor.authorSandanger, Torkjel M
dc.contributor.authorJohansson, Mattias
dc.date.accessioned2022-01-03T12:36:52Z
dc.date.available2022-01-03T12:36:52Z
dc.date.issued2021-05-25
dc.description.abstractSystemic inflammation markers have been linked to increased cancer risk and mortality in a number of studies. However, few studies have estimated pre-diagnostic associations of systemic inflammation markers and cancer risk. Such markers could serve as biomarkers of cancer risk and aid in earlier identification of the disease. This study estimated associations between pre-diagnostic systemic inflammation markers and cancer risk in the prospective UK Biobank cohort of approximately 440,000 participants recruited between 2006 and 2010. We assessed associations between four immune-related markers based on blood cell counts: systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and risk for 17 cancer sites by estimating hazard ratios (HR) using flexible parametric survival models. We observed positive associations with risk for seven out of 17 cancers with SII, NLR, PLR, and negative associations with LMR. The strongest associations were observed for SII for colorectal and lung cancer risk, with associations increasing in magnitude for cases diagnosed within one year of recruitment. For instance, the HR for colorectal cancer per standard deviation increment in SII was estimated at 1.09 (95% CI 1.02–1.16) in blood drawn five years prior to diagnosis and 1.50 (95% CI 1.24–1.80) in blood drawn one month prior to diagnosis. We observed associations between systemic inflammation markers and risk for several cancers. The increase in risk the last year prior to diagnosis may reflect a systemic immune response to an already present, yet clinically undetected cancer. Blood cell ratios could serve as biomarkers of cancer incidence risk with potential for early identification of disease in the last year prior to clinical diagnosis.en_US
dc.identifier.citationNøst TH, Alcala, Urbarova, Byrne, Guida, Sandanger, Johansson. Systemic inflammation markers and cancer incidence in the UK Biobank. European Journal of Epidemiology (EJE). 2021en_US
dc.identifier.cristinIDFRIDAID 1936412
dc.identifier.doi10.1007/s10654-021-00752-6
dc.identifier.issn0393-2990
dc.identifier.issn1573-7284
dc.identifier.urihttps://hdl.handle.net/10037/23575
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.relation.journalEuropean Journal of Epidemiology (EJE)
dc.relation.projectIDNorges forskningsråd: 262111en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/FRIMED2-FRIPRO/262111/Norway/Identifying biomarkers of metastatic lung cancer using Gene expression, DNA methylation and microRNAs in blood prior to clinical diagnosis//en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/RCN/FRIHUMSAM/213577/Norway/Are reductions in environmental burdens of industrial organic contaminants in rich countries achieved partly by export of toxic waste?//en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en_US
dc.titleSystemic inflammation markers and cancer incidence in the UK Biobanken_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record